Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFα agents
Open Access
- 3 September 2012
- journal article
- review article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 10 (12) , 889-897
Abstract
Summary: Drug‐induced lupus erythematosus (DILE) is a lupus‐like syndrome temporally related to continuous drug exposure which resolves upon drug discontinuation. There are currently no standard diagnostic criteria for DILE. Findings include skin manifestations, arthritis, serositis, anti‐nuclear and anti‐histone antibodies positivity. Similarly to idiopathic lupus erythematosus, DILE can be divided into systemic (SLE), subacute cutaneous (SCLE) and chronic cutaneous lupus (CCLE). Systemic DILE presents as a milder version of idiopathic SLE, and the drugs most frequently implicated are hydralazine, procainamide and quinidine. Anti‐TNFα therapies are the latest class of medications found to be associated, although rarely, with a “lupus‐like” syndrome, which is however clinically distinct from classical DILE. Drug‐induced SCLE is the most common form of DILE. It is very similar to idiopathic SCLE in terms of clinical and serologic characteristics. The most commonly implicated drugs are antihypertensive drugs and terbinafine, but in recent years also proton pump inhibitors and chemotherapeutic agents have been associated. Drug‐induced CCLE is very rare and usually caused by fluorouracil agents and NSAIDS, but some cases have induced by pantoprazole and anti‐TNFα agents.Keywords
This publication has 60 references indexed in Scilit:
- Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpartBritish Journal of Dermatology, 2011
- Drug-Induced Lupus ErythematosusDrug Safety, 2011
- Understanding the Epidemiology and Progression of Systemic Lupus ErythematosusSeminars in Arthritis and Rheumatism, 2010
- Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosusBritish Journal of Dermatology, 2009
- Chemotherapy-induced subacute lupus erythematosusLupus, 2009
- Bortezomib-Induced Lupus Erythematosus TumidusThe Oncologist, 2009
- Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literatureJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008
- A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunityBritish Journal of Dermatology, 2006
- Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritisNephrology Dialysis Transplantation, 2005
- Subacute Cutaneous Lupus Erythematosus Induced by NifedipineJournal of Cutaneous Medicine and Surgery, 2003